These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 1524952)

  • 1. Adoptive immunotherapy of cancer: biological response modifiers and cytotoxic cell therapy.
    Hillman GG; Haas GP; Wahl WH; Callewaert DM
    Biotherapy; 1992; 5(2):119-29. PubMed ID: 1524952
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interleukin-2: Old and New Approaches to Enhance Immune-Therapeutic Efficacy.
    Dhupkar P; Gordon N
    Adv Exp Med Biol; 2017; 995():33-51. PubMed ID: 28321811
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enhancing adoptive immunotherapy of cancer.
    Westwood JA; Berry LJ; Wang LX; Duong CP; Pegram HJ; Darcy PK; Kershaw MH
    Expert Opin Biol Ther; 2010 Apr; 10(4):531-45. PubMed ID: 20132063
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bio-immunotherapy for cancer in experimental studies and clinical application: current status and future challenges.
    Shen RN; Lu L; Kaiser HE; Broxmeyer HE
    In Vivo; 1994; 8(5):643-52. PubMed ID: 7727711
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epigenetic modifiers in immunotherapy: a focus on checkpoint inhibitors.
    Terranova-Barberio M; Thomas S; Munster PN
    Immunotherapy; 2016 Jun; 8(6):705-19. PubMed ID: 27197539
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biological Response Modifier in Cancer Immunotherapy.
    Liu R; Luo F; Liu X; Wang L; Yang J; Deng Y; Huang E; Qian J; Lu Z; Jiang X; Zhang D; Chu Y
    Adv Exp Med Biol; 2016; 909():69-138. PubMed ID: 27240457
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Antitumoral action of interferons and interleukins in combination with radiotherapy. Part I: immunologic basis].
    Herskind C; Fleckenstein K; Lohr J; Li CY; Wenz F; Lohr F
    Strahlenther Onkol; 2004 Apr; 180(4):187-93. PubMed ID: 15057428
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Combination of chemotherapy and immunotherapy in man--review].
    Ohnuma T
    Gan To Kagaku Ryoho; 1990 Aug; 17(8 Pt 1):1428-36. PubMed ID: 1697154
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combination of BRMs with chemotherapy.
    Tursz T
    Am J Med; 1995 Dec; 99(6A):56S-58S. PubMed ID: 8585538
    [No Abstract]   [Full Text] [Related]  

  • 10. Biological response modifiers (BRM), chemotherapy, and activated cytotoxic leukocyte subsets: strategies for rational design of apheresis-based cancer immunotherapies.
    Stevenson HC; Klein HG
    Prog Clin Biol Res; 1990; 337():559-65. PubMed ID: 2353018
    [No Abstract]   [Full Text] [Related]  

  • 11. [Immunomodulation in cancer. What do we do and where do we go?].
    Rodríguez Orozco AR; Serriteño NM
    Rev Alerg Mex; 2005; 52(2):96-101. PubMed ID: 16158783
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combination therapy with BRMs in cancer and infectious diseases.
    Garaci E; Pica F; Rasi G; Palamara AT; Favalli C
    Mech Ageing Dev; 1997 Jun; 96(1-3):103-16. PubMed ID: 9223114
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Palliative therapy in cancer. 6. Quality of life and BRM therapy in cancer-patients].
    Urushizaki I
    Gan To Kagaku Ryoho; 1990 Oct; 17(10):2119-29. PubMed ID: 1699499
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enhanced anti-metastatic efficacy of IL-2 activated NK (A-NK) cells with novel benzothiazoles.
    Goldfarb RH; Kitson RP; Brunson KW; Yoshino K; Hirota N; Kirii Y; Kotera Y; Inoue Y; Ohashi M
    Anticancer Res; 1999; 19(3A):1663-7. PubMed ID: 10470098
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biological response modifiers in cancer.
    Reang P; Gupta M; Kohli K
    MedGenMed; 2006 Nov; 8(4):33. PubMed ID: 17415315
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The promising alliance of anti-cancer electrochemotherapy with immunotherapy.
    Calvet CY; Mir LM
    Cancer Metastasis Rev; 2016 Jun; 35(2):165-77. PubMed ID: 26993326
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biological response modifiers for the therapy of cancer.
    Herberman RB
    Ann Allergy; 1985 May; 54(5):376-80. PubMed ID: 3994067
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Interactions of radiation and biological response modifiers (BRMs) in the treatment of malignant tumor].
    Mitsuhashi N; Takahashi M; Okazaki A; Niibe H
    Gan No Rinsho; 1990 Oct; 36(13):2272-7. PubMed ID: 2250347
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lymphokines, monoclonal antibodies, and other biological response modifiers in the treatment of cancer.
    Oldham RK; Thurman GB; Talmadge JE; Stevenson HC; Foon KA
    Cancer; 1984 Dec; 54(11 Suppl):2795-806. PubMed ID: 6437660
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Search for "weapons of mass destruction" for cancer -- immuno/ gene therapy comes of age.
    Wei MQ; Metharom P; Ellem KA; Barth S
    Cell Mol Immunol; 2005 Oct; 2(5):351-7. PubMed ID: 16368061
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.